European Journal of Nutrition

, Volume 44, Issue 6, pp 327–333

n–3 polyunsaturated fatty acids supplementation decreases asymmetric dimethyl arginine and arachidonate accumulation in aging spontaneously hypertensive rats

  • L. Raimondi
  • M. Lodovici
  • F. Visioli
  • L. Sartiani
  • L. Cioni
  • C. Alfarano
  • G. Banchelli
  • R. Pirisino
  • E. Cecchi
  • E. Cerbai
  • A. Mugelli



Plasma accumulation of asymmetric dimethyl arginine (ADMA) is considered as a risk factor for endothelial dysfunction and a strong predictor for coronary heart diseases. Eicosapentaenoic (EPA) and docosahexaenoic (DHA) increasing plasma levels have been positively associated with reduced cardiovascular mortality with a mechanism( s) yet unclear. We hypothesised that ADMA reduction might be a part of EPA and DHA beneficial effects on the cardiovascular system.


To verify this hypothesis we measured ADMA plasma levels in aged spontaneously hypertensive rats (SHR) supplemented for 8 weeks with EPA and DHA.


16–month–old SHR were supplemented with EPA and DHA (EPA–DHA) or with olive oil (1 g/kg/day; OLIVE). At the end of the treatments, the plasma of each animal was analysed for 1) the total fatty acid composition, by gas–cromatography, 2) ADMA levels, by high pressure liquid chromatography, 3) nitrite and homocysteine concentration by chemiluminescence and by polarisation immunoassay respectively. Moreover, the activity of dimethyl arginine dimethyl amino hydrolase, the main enzyme involved in ADMA metabolism, was measured spectrophotometrically in the kidney from each rat.


Animals supplemented with EPA and DHA showed: 1) lower ADMA and arachidonate plasma levels (587.4 ± 113.7 nM and 0.49 ± 0.11 mM respectively) than the values found in OLIVE rats (1365 ± 399 nM and 1.07 ± 0.07 mM respectively) 2) higher nitrite content (0.73 ± 0.05 µM) than OLIVE (0.23 ± 0.08 µM).


EPA and DHA supplementation reduced ADMA accumulation in SHR in parallel with a decrease of arachidonate availability. This finding suggests that the control of the inflammatory ground of endothelium might play an important role in EPA and DHA effect on this novel and highly predictive cardiovascular risk factor.

Key words

hypertension long chain fatty acids ADMA cardiovascular risk 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bucher HC, Hengstler P, Schindler C, Meier G (2002) N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112:298–304CrossRefPubMedGoogle Scholar
  2. 2.
    Kris-Etherton PM, Harris WS, Appel LJ (2003) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 23:20–30CrossRefGoogle Scholar
  3. 3.
    Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC (1995) Dietary Intake of Marine n-3 Fatty Acids, Fish Intake, and the Risk of Coronary Disease among Men. N Engl J Med 332:977–983CrossRefPubMedGoogle Scholar
  4. 4.
    Singh RB (1999) GISSI-Prevenzione trial. Lancet 354:1556–1557CrossRefPubMedGoogle Scholar
  5. 5.
    (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. The Lancet 354:447–455Google Scholar
  6. 6.
    Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F, on behalf of the GISSI-Prevenzione Investigators (2002) Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 105:1897CrossRefPubMedGoogle Scholar
  7. 7.
    Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL (2000) AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Stroke 31:2751–2766PubMedGoogle Scholar
  8. 8.
    Christon RA (2003) Mechanisms of action of dietary fatty acids in regulating the activation of vascular endothelial cells during atherogenesis. Nutr Rev 61:272–279CrossRefPubMedGoogle Scholar
  9. 9.
    Leaf A, Kang JX, Xiao YF, Billman GE (2003) Clinical Prevention of Sudden Cardiac Death by n-3 Polyunsaturated Fatty Acids and Mechanism of Prevention of Arrhythmias by n-3 Fish Oils. Circulation 107:2646–2652CrossRefPubMedGoogle Scholar
  10. 10.
    Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98:1842–1847PubMedGoogle Scholar
  11. 11.
    Boger RH (2003) The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59:824–833PubMedGoogle Scholar
  12. 12.
    Delles C, Schneider MP, John S, Gekle M, Schmieder RE (2002) Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 15:590–593CrossRefPubMedGoogle Scholar
  13. 13.
    Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, Reaven GM, Tsao PS (2002) Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 51:843–846CrossRefPubMedGoogle Scholar
  14. 14.
    Cerbai E, De Paoli P, Sartiani L, Lonardo G, Mugelli A (2003) Treatment with irbesartan counteracts the functional remodeling of ventricular myocytes from hypertensive rats. J Cardiovasc Pharmacol 41:804–812PubMedGoogle Scholar
  15. 15.
    Pettersson A, Uggla L, Backman V (1997) Determination of dimethylated arginines in human plasma by highperformance liquid chromatography. J Chromatogr B Biomed Sci Appl 692:257–262PubMedGoogle Scholar
  16. 16.
    Leiper JM, Santa MJ, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P (1999) Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343(Pt 1):209–214CrossRefPubMedGoogle Scholar
  17. 17.
    Achan V, Broadhead M, Malaki M, Whitley GS, Leiper J, MacAllister R, Vallance P (2003) Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23:1455–1459Google Scholar
  18. 18.
    Ogawa T, Kimoto M, Sasaoka K (1987) Occurrence of a new enzyme catalyzing the direct conversion of NG, NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 148:671–677CrossRefPubMedGoogle Scholar
  19. 19.
    Espey MG, Miranda KM, Pluta RM, Wink DA (2000) Nitrosative Capacity of Macrophages Is Dependent on Nitricoxide Synthase Induction Signals. J Biol Chem 275:11341–11347PubMedGoogle Scholar
  20. 20.
    Brunelli T, Pepe G, Marcucci R, Giusti B, Prisco D, Abbate R, Fedi S (2001) Comparison of three methods for total homocysteine plasma determination. Clin Lab 47:393–397PubMedGoogle Scholar
  21. 21.
    Visioli F, Rihn LL, Rodriguez de Turco EB, Kreisman NR, Bazan NG (1993) Free fatty acid and diacylglycerol accumulation in the rat brain during recurrent seizures is related to cortical oxygenation. J Neurochem 61:1835–1842PubMedGoogle Scholar
  22. 22.
    Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509PubMedGoogle Scholar
  23. 23.
    Kumar U, Shin Y, Wersinger C, Patel Y, Sidhu A (2003) Diminished expression of constitutive nitric oxide synthases in the kidney of spontaneously hypertensive rat. Clin Exp Hypertens 25:271–282CrossRefPubMedGoogle Scholar
  24. 24.
    Delachambre MC, Narce M, Asdrubal P, Poisson JP (1998) Changes in tissue polyunsaturated fatty acids with age, in spontaneously hypertensive rats. Lipids 33:795–801PubMedGoogle Scholar
  25. 25.
    Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99:3092–3095PubMedGoogle Scholar
  26. 26.
    Davis MR, Ortegon DP, Kerby JD, Ignarro LJ, Kashyap VS (2003) Endothelial dysfunction after arterial thrombosis is ameliorated by L-arginine in combination with thrombolysis. J Vasc Interv Radiol 14:233–239PubMedGoogle Scholar
  27. 27.
    Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS (2002) Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 90:974–982CrossRefPubMedGoogle Scholar
  28. 28.
    Bexis S, Lungershausen YK, Mano MT, Howe PR, Kong JQ, Birkle DL, Taylor DA, Head RJ (1994) Dietary fish oil administration retards blood pressure development and influences vascular properties in the spontaneously hypertensive rat (SHR) but not in the stroke prone-spontaneously hypertensive rat (SHR-SP). Blood Press 3:120–126PubMedGoogle Scholar
  29. 29.
    Trippodo NC, Frohlich ED (1981) Similarities of genetic (spontaneous) hypertension. Man and rat. Circ Res 48:309–319PubMedGoogle Scholar
  30. 30.
    Nagakura T, Matsuda S, Shichijyo K, Sugimoto H, Hata K (2000) Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma. Eur Respir J 16:861–865PubMedGoogle Scholar
  31. 31.
    Sperling RI (1991) Dietary omega-3 fatty acids: effects on lipid mediators of inflammation and rheumatoid arthritis. Rheum Dis Clin North Am 17:373–389PubMedGoogle Scholar
  32. 32.
    Sattar N (2004) Inflammation and endothelial dysfunction: intimate companions in the pathogenesis of vascular disease? Clin Sci (Lond)Google Scholar
  33. 33.
    Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I (2003) Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166:279–284CrossRefPubMedGoogle Scholar
  34. 34.
    Holm T, Aukrust P, Aagaard E, Ueland T, Haugstad TS, Kjekshus J, Simonsen S, Froland SS, Gullestad L, Andreassen AK (2002) Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension. Transplantation 74:1395–1400CrossRefPubMedGoogle Scholar
  35. 35.
    Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350:4–7PubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2004

Authors and Affiliations

  • L. Raimondi
    • 1
    • 2
  • M. Lodovici
    • 1
  • F. Visioli
    • 3
  • L. Sartiani
    • 1
  • L. Cioni
    • 1
  • C. Alfarano
    • 1
  • G. Banchelli
    • 1
  • R. Pirisino
    • 1
  • E. Cecchi
    • 1
  • E. Cerbai
    • 1
  • A. Mugelli
    • 1
  1. 1.Dept. of PharmacologyUniversity of FlorenceFlorenceItaly
  2. 2.Viale G. Pieraccini 6FlorenceItaly
  3. 3.Dept. of PharmacologicalSciences University of MilanMilanItaly

Personalised recommendations